Ken Griffin Minerva Neurosciences, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Minerva Neurosciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 12,915 shares of NERV stock, worth $18,210. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,915
Previous 25,764
49.87%
Holding current value
$18,210
Previous $57,000
63.16%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding NERV
# of Institutions
19Shares Held
1.95MCall Options Held
0Put Options Held
0-
Federated Hermes, Inc. Pittsburgh, PA1.35MShares$1.91 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA252KShares$355,4040.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny114KShares$160,8760.0% of portfolio
-
Geode Capital Management, LLC Boston, MA76.7KShares$108,1920.0% of portfolio
-
Black Rock Inc. New York, NY72.7KShares$102,4630.0% of portfolio
About Minerva Neurosciences, Inc.
- Ticker NERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 5,340,190
- Market Cap $7.53M
- Description
- Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein ...